|Day Low/High||303.70 / 309.21|
|52 Wk Low/High||291.10 / 442.00|
Dips in the pharma name have been bought, a sign of demand that presents a relatively low-risk buying opportunity.
This stock is testing resistance and could push back up to last year's highs.
There are nearly too many surging sectors to count.
Icahn may have a tough time finding interest in this behemoth.
Static doesn't work in this industry. Pipelines work.
The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
Usually I prefer to buy strength as opposed to buying weakness, but I want to depart from my normal behavior with this biotech.
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
Hillary isn't the only one who seems to favor workers over capital. Trump does, too.
Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.
The October jobs report is released on Friday, November 4th at 8:30 a.m. Eastern.
It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.